{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-022219","form_type":"8-K","ticker":"ORIC","cik":"0001796280","company_name":"Oric Pharmaceuticals, Inc.","filed_at":"2025-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.905213+00:00","generated_at":"2026-05-26T17:17:33.887098+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated","bullets":["Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.","R&D expenses Q4 $32.0M (up 31% YoY), FY2024 $114.1M (up 34%).","G&A expenses Q4 $7.6M (up 10%), FY2024 $28.8M (up 13%).","Expects seven data readouts for ORIC-114, ORIC-944 over 18 months; potential registrational trials in 2H25/early 2026.","Entered J&J collaboration for ORIC-114 + amivantamab in NSCLC; completed $125M private placement."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-022219","json":"https://secwatch.observer/filing/0000950170-25-022219.json","markdown":"https://secwatch.observer/filing/0000950170-25-022219.md","text":"https://secwatch.observer/filing/0000950170-25-022219.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025022219/0000950170-25-022219-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1796280/000095017025022219/oric-20250218.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T17:17:33.887098+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}